TY - JOUR
T1 - The national cancer institute cohort consortium
T2 - An international pooling collaboration of 58 cohorts from 20 countries
AU - Swerdlow, Anthony J.
AU - Harvey, Chinonye E.
AU - Milne, Roger L.
AU - Pottinger, Camille A.
AU - Mvachon, Celine
AU - Rwilkens, Lynne
AU - Gapstur, Susan M.
AU - Johansson, Mattias
AU - Weiderpass, Elisabete
AU - Winn, Deborah
N1 - Funding Information:
preparation of the study database. NCI has developed and funded certain targetted initiatives within the Cohort Consortium to address NCI high programmatic and scientific research needs, but usually funding for projects has been obtained from investigator-initiated grants, from NCI or other sources. In the 171 published Consortium articles that stated funding sources, all but two cited the NCI as a source (but this can include support of individual cohorts, not just the overall pooling) and 30 cited other NIH Institutes (Bethesda, MD), especially the National Institute on Aging (22) and the National Institute of Environmental Health Sciences (14), whereas the American Cancer Society contributed to funding of 43. Three quarters of the papers cited funding solely from the United States, and a tenth by three or more countries.
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/11
Y1 - 2018/11
N2 - Cohort studies have been central to the establishment of the known causes of cancer. To dissect cancer etiology in more detail-for instance, for personalized risk prediction and prevention, assessment of risks of subtypes of cancer, and assessment of small elevations in risk-there is a need for analyses of far larger cohort datasets than available in individual existing studies. To address these challenges, the NCI Cohort Consortium was founded in 2001. It brings together 58 cancer epidemiology cohorts from 20 countries to undertake largescale pooling research. The cohorts in aggregate include over nine million study participants, with biospecimens available for about two million of these. Research in the Consortium is undertaken by >40 working groups focused on specific cancer sites, exposures, or other research areas. More than 180 publications have resulted from the Consortium, mainly on genetic and other cancer epidemiology, with high citation rates. This article describes the foundation of the Consortium; its structure, governance, and methods of working; the participating cohorts; publications; and opportunities. The Consortium welcomes newmembers with cancer-oriented cohorts of 10,000 or more participants and an interest in collaborative research.
AB - Cohort studies have been central to the establishment of the known causes of cancer. To dissect cancer etiology in more detail-for instance, for personalized risk prediction and prevention, assessment of risks of subtypes of cancer, and assessment of small elevations in risk-there is a need for analyses of far larger cohort datasets than available in individual existing studies. To address these challenges, the NCI Cohort Consortium was founded in 2001. It brings together 58 cancer epidemiology cohorts from 20 countries to undertake largescale pooling research. The cohorts in aggregate include over nine million study participants, with biospecimens available for about two million of these. Research in the Consortium is undertaken by >40 working groups focused on specific cancer sites, exposures, or other research areas. More than 180 publications have resulted from the Consortium, mainly on genetic and other cancer epidemiology, with high citation rates. This article describes the foundation of the Consortium; its structure, governance, and methods of working; the participating cohorts; publications; and opportunities. The Consortium welcomes newmembers with cancer-oriented cohorts of 10,000 or more participants and an interest in collaborative research.
UR - http://www.scopus.com/inward/record.url?scp=85055915244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055915244&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-18-0182
DO - 10.1158/1055-9965.EPI-18-0182
M3 - Review article
C2 - 30018149
AN - SCOPUS:85055915244
SN - 1055-9965
VL - 27
SP - 1307
EP - 1319
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 11
ER -